Sagimet’s denifanstat delivered significant improvements in disease activity and fibrosis for patients with metabolic dysfunction-associated steatohepatitis.
Injecting lung stem cells into the bloodstream of mice with idiopathic pulmonary fibrosis improved their lung function, setting the stage for human trials.